12
Participants
Start Date
November 30, 2006
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
131-I-chTNT-1/B MAB
The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.
University of Pennsylvania, Philadelphia
Medical University of South Carolina, Charleston
University Hospitals Case Medical Center, Cleveland
Barrow Neurological Institute, Phoenix
Lead Sponsor
Peregrine Pharmaceuticals
INDUSTRY